ストックスクリーナーアプリを入手
1.34
3.08%
0.04
前日終値:
$1.30
開ける：
$1.3
24時間の取引高:
246.71K
Relative Volume:
0.34
時価総額：
$96.82M
収益：
-
当期純損益:
$-292.19M
株価収益率:
-0.2952
EPS:
-4.54
ネットキャッシュフロー:
$-208.41M
1週間 パフォーマンス:
+0.75%
1か月 パフォーマンス:
-18.29%
6か月 パフォーマンス:
+10.74%
1年 パフォーマンス:
-57.86%
1日の値動き範囲:
$1.28
$1.345
1週間の範囲:
$1.28
$1.425
52週間の値動き範囲:
$1.01
$4.00
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
名前
Zentalis Pharmaceuticals Inc
セクター
電話
(858) 263-4333
住所
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.34 | 93.93M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.01 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.62 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
437.90 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.89 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.22 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-12 | アップグレード | Wedbush | Underperform → Neutral |
| 2024-06-20 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-06-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | ダウングレード | Wedbush | Neutral → Underperform |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 開始されました | Cowen | Outperform |
| 2022-04-06 | 開始されました | Wells Fargo | Overweight |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-29 | 開始されました | Oppenheimer | Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-01-20 | 開始されました | Wedbush | Outperform |
| 2020-09-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Guggenheim | Buy |
| 2020-04-28 | 開始されました | Jefferies | Buy |
| 2020-04-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - Setenews
Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Zentalis Pharmaceuticals, Inc. $ZNTL - Defense World
What indicators show strength in Zentalis Pharmaceuticals Inc.Portfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com
Why analysts upgrade Zentalis Pharmaceuticals Inc. stockEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming base2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha
Multi asset correlation models including Zentalis Pharmaceuticals Inc.Earnings Beat & Weekly High Conviction Trade Ideas - newser.com
How geopolitical tensions affect Zentalis Pharmaceuticals Inc. stockBuy Signal & Momentum Based Trading Ideas - newser.com
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - Defense World
Can Zentalis Pharmaceuticals Inc. stock reach $100 price target2025 Key Highlights & Weekly High Return Stock Opportunities - newser.com
FY2025 Earnings Estimate for ZNTL Issued By Leerink Partnrs - Defense World
Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Analysts - Defense World
Wedbush Reiterates “Neutral” Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Morgan Stanley Maintains Zentalis Pharmaceuticals (ZNTL) Equal-Weight Recommendation - MSN
Relative strength of Zentalis Pharmaceuticals Inc. in sector analysisPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z - GuruFocus
What recovery options are there for Zentalis Pharmaceuticals Inc.2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Zentalis Pharmaceuticals Inc (ZNTL) looking to reclaim success with recent performance - Setenews
Zentalis Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Zentalis Pharmaceuticals stock price target lowered to $2 at Leerink Partners - Investing.com Canada
Zentalis Pharmaceuticals Cuts Losses And Draws Analyst Support - Finimize
Zentalis (ZNTL) Progresses DENALI Trial for Ovarian Cancer Treat - GuruFocus
Zentalis Pharmaceuticals Inc (ZNTL) 財務データ
収益
当期純利益
現金流量
EPS
Zentalis Pharmaceuticals Inc (ZNTL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):